Search
Investigators are looking at how and why the breast cancer drug trastuzumab sometimes causes long-lasting and potentially serious cardiac side effects.
Learn about how to cope with grief during the holidays from MSK Experts.
Expand your knowledge of melanoma with these surprising facts.
Adding idelalisib (Zydelig®) to a standard chemotherapy regimen of bendamustine and rituximab (BR) significantly increases progression-free survival (PFS) and overall survival (OS) in patients with relapsed or treatment-resistant chronic lymphocytic leukemia (CLL) as compared with BR alone, according to new findings presented by a Memorial Sloan Kettering (MSK) investigator on behalf of his international co-investigators. Results from the phase III study were presented as part of the press program at this year’s American Society of Hematology annual meeting.
A new type of cancer therapy that targets an oncometabolite produced dramatic results in patients with advanced leukemia in an early-phase clinical trial.
Researchers at MSK have been at the forefront of developing new treatments for advanced melanoma for many years. Learn more about the latest therapies.
Learn from neurosurgeon Viviane Tabar about the standard treatment for glioblastoma, which involves surgery, chemotherapy, and radiation.
State-of-the-art facility will be reduced by 76 feet while continuing to meet increasing demand for cancer care.
Learn about the latest advances in lung cancer treatment at MSK.
Conozca los últimos avances en el tratamiento contra el cáncer pulmonar en MSK.